Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • Tango Therapeutics' Cash from Financing Activities rose 578.68% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 9150.16%. This contributed to the annual value of $47.7 million for FY2024, which is 4215.96% down from last year.
  • As of Q3 2025, Tango Therapeutics' Cash from Financing Activities stood at $2.5 million, which was up 578.68% from $581000.0 recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Cash from Financing Activities peaked at $327.8 million during Q3 2021, and registered a low of -$746000.0 during Q2 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $718000.0 (2022), whereas its average is $25.9 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 308101.9% in 2021, then skyrocketed by 7094424.78% in 2023.
  • Over the past 5 years, Tango Therapeutics' Cash from Financing Activities (Quarter) stood at -$120000.0 in 2021, then surged by 539.17% to $527000.0 in 2022, then soared by 178.37% to $1.5 million in 2023, then crashed by 33.95% to $969000.0 in 2024, then surged by 162.23% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $581000.0 for Q2 2025, and $2000.0 during Q1 2025.